ImpriMed Launches New Diagnostic Services for Canine Lymphoma
October 19, 2021 08:00 ET
|
ImpriMed, Inc.
PALO ALTO, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- ImpriMed, Inc., a leading functional precision medicine company in veterinary oncology that provides a personalized drug response profiling...
ImpriMed Launches Chemo Response Prediction and Immunophenotyping Services for Canine Lymphoma
May 24, 2021 08:00 ET
|
ImpriMed, Inc.
PALO ALTO, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- ImpriMed, Inc., a leading veterinary precision medicine biotech startup today announced the launching of their most advanced precision medicine...
ImpriMed Raises $8M to Commercialize AI-Driven Personalized Drug Response Prediction Service in Pet Cancer Market
April 13, 2021 08:00 ET
|
ImpriMed, Inc.
PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- ImpriMed, Inc., a leading veterinary precision medicine startup has recently closed a total of $8 million in Pre-Series A funding with $7.7...
Rhizen Pharmaceuticals S.A. announces initiation of Phase 2 study of RV1001 in dogs with T- or B-cell Lymphoma
September 22, 2015 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. has announced the initiation of Phase 2 study of RV1001, a novel, oral selective inhibitor of PI3K...